Leadership & Pay ·
Alkermes plc appointed Blair C. Jackson as President and Chief Executive Officer, effective August 1, 2026
ALKSAlkermes plc.
Alkermes plc appointed Blair C. Jackson as President and Chief Executive Officer, effective August 1, 2026. The Board expanded the board size from nine to ten directors and elected Mr. Jackson to serve on the board and its Financial Operating Committee. His compensation package includes a $900,000 annual base salary and a target cash performance award equal to 100% of that salary. He received a one-time promotion equity award valued at $5 million, comprising approximately 55% performance-vesting restricted stock units with a three-year vesting period and 45% time-vesting stock options vesting over four years. Additionally, he was granted a special incentive performance equity award with a target value of $3 million in stock options vesting upon specific share price milestones after two years of service. The employment agreement provides for severance benefits equal to one-and-a-half times base salary and prior incentives if terminated without cause or for good reason, and double compensation following a change-in-control termination. Alkermes plc operates in the pharmaceutical industry, developing and commercializing treatments for addiction, mental health, and neurological disorders.